ReviewClinics and practice2023
Preventing Respiratory Viral Diseases with Antimicrobial Peptide Master Regulators in the Lung Airway Habitat.
Review in Clinics and practice, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 15 citations in OpenAlex.
- Role of antimicrobial peptide-based biomaterials in respiratory tract infections control.BMC microbiology · 2026Review
- Comparative characterization of bronchial and nasal mucus reveals key determinants of influenza A virus inhibition.mSphere · 2025Article
- Epigenetic horizons in aquaculture: unlocking sustainable fish production.Fish physiology and biochemistry · 2025Review
- Mucosal immunity and vaccination strategies: current insights and future perspectives.Molecular biomedicine · 2025Review
- Revisiting the potential of natural antimicrobial peptides against emerging respiratory viral disease: a review.3 Biotech · 2025Review
- Article
- Antimicrobial Peptides (AMPs) and the Microbiome in Preterm Infants: Consequences and Opportunities for Future Therapeutics.International journal of molecular sciences · 2024Review
- Lysozyme: A Natural Product with Multiple and Useful Antiviral Properties.Molecules (Basel, Switzerland) · 2024Review
- Mucosal Immunity against SARS-CoV-2 in the Respiratory Tract.Pathogens (Basel, Switzerland) · 2024Review
- Editorial: Preventative strategies to stop the spread of antibiotic resistance.Frontiers in antibiotics · 2023Article
- Cathelicidin-derived antiviral peptide inhibits herpes simplex virus 1 infection.Frontiers in microbiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The vast surface area of the respiratory system acts as an initial site of contact for microbes and foreign particles. The whole respiratory epithelium is covered with a thin layer of the airway and alveolar secretions. Respiratory secretions contain host defense peptides (HDPs), such as defensins and cathelicidins, which are the best-studied antimicrobial components expressed in the respiratory tract. HDPs have an important role in the human body's initial line of defense against pathogenic microbes. Epithelial and immunological cells produce HDPs in the surface fluids of the lungs, which act as endogenous antibiotics in the respiratory tract. The production and action of these antimicrobial peptides (AMPs) are critical in the host's defense against respiratory infections. In this study, we have described all the HDPs secreted in the respiratory tract as well as how their expression is regulated during respiratory disorders. We focused on the transcriptional expression and regulation mechanisms of respiratory tract HDPs. Understanding how HDPs are controlled throughout infections might provide an alternative to relying on the host's innate immunity to combat respiratory viral infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.